Kyoto University · 의학
Hiroshi Date 교수의 연구실은 주로 폐 및 흉선 종양의 치료 전략과 생존 예후를 중심으로 한 임상 및 기초 연구를 수행하고 있습니다. 특히 난소성 종양의 수술적 치료 결과, 이식 전 대기압 조건에서의 폐 기증자 폐의 생존 능력, 그리고 폐암에서 저산소성 반응과 당대사 재편성에 의한 화학요법 내성 메커니즘을 규명하는 데 초점을 맞추고 있습니다. 이는 종양 생물학과 이식의학을 융합한 혁신적인 접근을 통해 환자의 생존율 향상에 기여하고자 하는 연구 정신을 반영합니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
In this study, PORT did not increase RFS or OS for stage II or III thymoma but increased RFS for stage II and III thymic carcinoma.
Although LDLLT patients were in a worse preoperative condition than CLT patients, LDLLT patients demonstrated survival rates similar to CLT patients. LDLLT is a viable option for patients too ill to survive a long waiting time for cadaveric donors.
Lung cancer treatment is difficult owing to chemoresistance. Hypoxia-inducible factor 1 (HIF-1) and HIF-1-induced glycolysis are correlated with chemoresistance; however, this is not evident in lung cancer. We investigated the effect of HIF-1α and carbonic anhydrase IX (CAIX), a transmembrane protein neutralizing intracellular acidosis, on chemoresistance and prognosis of lung cancer patients after induction chemoradiotherapy. Associations of HIF-1α, glucose transporter 1 (GLUT1), and CAIX with
The lung is the only organ to which oxygen may be supplied after its blood supply is stopped. Before this study, we were not certain whether lung cells were able to maintain aerobic metabolism with the oxygen in the alveoli during preservation. Excised rabbit lungs were used to measure changes in the concentration of oxygen and carbon dioxide in the airway and changes in glucose, glucose-6-phosphate, lactate, adenosine triphosphate, and phosphocreatine levels in the lung tissue during preservati
